Chugai's Kadcyla (trastuzumab emtansine) Receives MHLW's Approval for Adjuvant Therapy of HER2-Positive Early Breast Cancer
Shots:
- The approval is based on P-III KATHERINE study assessing Kadcyla (100/160mg- IV) adjuvant therapy in 1486 patients with HER2+ early BC who did not have pathologic complete response following neoadjuvant therapy including Herceptin
- The results showed the superiority of Kadcyla over Herceptin in terms of the 1EPs of invasive disease-free survival. The safety profile of the therapy in the study was consistent with the previously approved treatment of HER2-positive metastatic BC- and was well-tolerated as an adjuvant treatment in HER2-positive early BC
- Kadcyla is an ADC and a postoperative new treatment option to improve prognosis in the treatment of HER2-positive early BC when pCR is not obtained by neoadjuvant therapy
Ref: Chugai | Image: Pune365
Related News: Roche’s Kadcyla (trastuzumab emtansine) Receives Health Canada’s Approval for The Treatment of HER2-Positive Early Breast Cancer After Surgery
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
